
Luvometinib Tablets Approved in China 丨A Next-Generation MEK1/2 Inhibitor for Rare MAPK-Driven Tumors
China’s National Medical Products Administration (NMPA) has officially approved Luvometinib Tablets (brand name Fumaining®, development code…

China’s National Medical Products Administration (NMPA) has officially approved Luvometinib Tablets (brand name Fumaining®, development code…

When it comes to medicine, most people assume that taking a drug is enough for…

Recently, Fujian Shengdian Pharmaceutical Co., Ltd., a subsidiary of Hengrui Medicine, received approval from the…

In the rapidly evolving field of healthcare, the term “innovative drug” has gained significant attention.…

How strong is China innovative drug industry? The answer is increasingly evident as the nation…

The landscape of China pharma distribution trends 2025 is set to experience remarkable transformation as…

In recent years, the question “How to Import Medicines from China” has become one of…

May 29, 2025 — The National Medical Products Administration (NMPA) has granted conditional approval through…

China’s National Medical Products Administration (NMPA) has officially approved Inpegsomatropin Injection, a first-in-class, innovative long-acting…

China’s pharmaceutical market is growing rapidly and has become one of the world’s largest and…